Novo Nordisk licenses Nanexa drug tech in deal worth up to €1.17 bln

🌐 Investing.com (CY) —
Novo Nordisk licenses Nanexa drug tech in deal worth up to €1.17 bln

AI Summary

Novo Nordisk has licensed Nanexa's drug technology in a deal potentially worth up to €1.17 billion, marking a significant pharmaceutical industry transaction. This agreement highlights ongoing innovation and collaboration in drug development.

Markets Deals Health Novo Nordisk Nanexa drug technology licensing deal pharmaceuticals investment

Read original source →